Recombinant CD28 (Theralizumab Biosimilar) antibody
This Humanized Chimeric antibody specifically detects CD28 (Theralizumab Biosimilar) in not_set. It exhibits reactivity toward Human.
Catalog No. ABIN7598037
-15% Promotion 2026
$340.97
save $60.17 (-15 %)
Plus shipping costs $50.00, if applicable $20.00 dry ice
Shipping to:
United States
Delivery in 12 to 14 Business Days
Quick Overview for Recombinant CD28 (Theralizumab Biosimilar) antibody (ABIN7598037)
Target
CD28 (Theralizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Chimeric
Conjugate
This CD28 (Theralizumab Biosimilar) antibody is un-conjugated
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Research Grade Theralizumab Biosimilar Antibody
-
Specificity
- CD28, TP44, T-cell-specific surface glycoprotein CD28
-
Purification
- Protein A or G purified from cell culture supernatant.
-
Purity
- >95 % by SDS-PAGE.
-
Isotype
- IgG4
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 0.01M PBS, pH 7.4.
-
Storage
- 4 °C,-20 °C,-80 °C
-
Storage Comment
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
-
Expiry Date
- 12 months
-
-
- CD28 (Theralizumab Biosimilar)
-
Alternative Name
- Theralizumab Biosimilar
-
Target Type
- Biosimilar
-
Background
- CD28, TP44, T-cell-specific surface glycoprotein CD28
-
UniProt
- P10747
-
CAS-No
- 906068-56-2
Target
-
You are here:
